"Hypersynchronisation" by tissue velocity imaging in patients with cardiac amyloidosis

Heart

Volumn 95, Issue 3, 2009, Pages 234-240

  Bellavia, D ^a   Pellikka, P A ^a   Abraham, T P ^a   Al Zahrani, G B ^a   Dispenzieri, A ^a   Oh, J K ^a   Espinosa, R E ^a   Scott, C G ^a   Miyazaki, C ^a   Miller, F A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIAC MECHANICAL DYSSYNCHRONY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART CONTRACTION; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE VELOCITY IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AMYLOIDOSIS; ATRIOVENTRICULAR NODE; BIOLOGICAL MARKERS; BLOOD PRESSURE; BUNDLE-BRANCH BLOCK; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 62149128920     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2007.140343     Document Type: Article

References (15)

1. James TN. Pathology of the cardiac conduction system in amyloidosis. Ann Intern Med 1966;65:28-36.
2. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997;30:1046-51.
3. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004;44:1834-40.
4. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
5. Tei C, Dujardin KS, Hodge DO, et al. Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996;28:658-64.
6. Lane RE, Chow AW, Chin D, et al. Selection and optimisation of biventricular pacing: the role of echocardiography. Heart 2004;90(suppl 6):vi10-6.
7. Yu CM, Lin H, Zhang Q, et al. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 2003;89:54-60.
8. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med 1977;62:677-86.
9. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984;3:107-13.
10. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
11. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7.
12. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-7.
13. Brenner DA, Jain M, Pimental DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
14. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60.
15. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-42.